Forward Partners-backed Sonrai Analytics, a Belfast-based AI precision medicine company, has appointed Paul Jones as chairman.

Jones has experience of precision medicine and genomics. He is currently chief executive of Vortex Biosciences, where he is leading a new service-based strategy to capture and isolate circulating tumour cells from blood to support the development of personalised medicines, guide therapy selection and monitor cancer.

He previously worked as head of population genomics at Illumina, leading the team that created, developed and actively managed large-scale programmes across more than 50 countries.

Jones was the founding chief executive of Genomic Enterprises, the arm of Genomics England responsible for all commercial aspects of the 100,000 Genomes Project. He has also been director and leader of global life sciences at Cisco and head of global e-marketing and e-sales at Novartis.

Professor Darragh McArt, founder and chief executive of Sonrai Analytics, said: “[Jones] has a distinguished career in the life sciences industry characterised by visionary leadership and a commitment to advancing healthcare through cutting-edge technologies. His appointment reflects Sonrai’s dedication to driving innovation and excellence in precision medicine and will provide valuable insight as we continue to expand our global footprint.”

Luke Smith, investment partner at Forward Partners, said: “Paul has been at the forefront of data-driven and precision healthcare, making him a brilliant fit for the exciting opportunity at Sonrai.”

Jones commented: “I see tremendous potential for us to make a significant impact. The convergence of advanced AI technologies and precision medicine offers unprecedented opportunities for improving patient care, and Sonrai is exceptionally well-positioned to lead in this space. I look forward to working closely with the team at Sonrai to propel its mission to advance precision medicine and, ultimately, make a positive difference in the lives of patients worldwide.”